<?xml version="1.0" encoding="UTF-8"?>
<p class="p">It is estimated that
 <italic class="italic"> Candida </italic>infections (
 <italic class="italic">Candida albicans</italic>,
 <italic class="italic"> Candida parapsilosis</italic>,
 <italic class="italic"> Candida glabrata</italic>,
 <italic class="italic"> Candida tropicalis</italic>, and
 <italic class="italic"> Candida krusei</italic>) [
 <xref rid="B10" ref-type="bibr" class="xref">10</xref>] correspond to 80% of the fungal infections detected in the urinary and blood flow of patients, as well as in the surgical environment [
 <xref rid="B11" ref-type="bibr" class="xref">11</xref>]. Polyenes, flucytosine, and azole drugs are the most recommended for the treatment of
 <italic class="italic"> Candida</italic> infections [
 <xref rid="B12" ref-type="bibr" class="xref">12</xref>]. Some drugs with antifungal properties have inhibited the enzyme sterol 14-
 <italic class="italic">Î±</italic> demethylase, CYP51 [
 <xref rid="B13" ref-type="bibr" class="xref">13</xref>], which is required for the biosynthesis of ergosterol, essential for the fungal membrane maintenance [
 <xref rid="B14" ref-type="bibr" class="xref">14</xref>]. Thus, recently
 <italic class="italic"> in silico</italic> studies examining the drug-protein interaction by the molecular docking method [
 <xref rid="B15" ref-type="bibr" class="xref">15</xref>] have become a powerful tool to characterize possible compound activity in a given protein [
 <xref rid="B16" ref-type="bibr" class="xref">16</xref>].
</p>
